Search Result

Results for "

Glucokinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Glucokinase (29) Glucosidase (1)
By Research Areas:	Cancer (2) Endocrinology (1) Metabolic Disease (32) Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Recombinant Proteins

Antibodies

Targets Recommended: Glucokinase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P2761

*Glucokinase*	Others	Others
Glucokinase is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-144287

Glucokinase activator 3	Glucokinase	Endocrinology
Glucokinase activator 3 is a potent and full Glucokinase (GK) activator with an AC₅₀ of 38 nM. Glucokinase activator 3 has the potential for the research of type 2 diabetes .

HY-147254

Cadisegliatin TTP-399	Glucokinase	Metabolic Disease
Cadisegliatin (TTP-399) is a potential, orally active liver-selective glucokinase (GK) activator. Cadisegliatin has antihyperglycaemic activity. Cadisegliatin can be used for the research of type 2 diabetes .

HY-10595

RO-28-1675 2 Publications Verification	Glucokinase	Metabolic Disease
RO-28-1675 is a potent allosteric glucokinase (GK) activator with an EC₅₀ of 54 nM. RO-28-1675 can be used for the research of type 2 diabetes .

HY-15675

AZD1656	Glucokinase	Metabolic Disease
AZD1656 is a potent, selective and orally active *glucokinase* activator with an EC₅₀ of 60 nM. AZD1656 has the potential for type 2 diabetes research .

HY-131940

3-O-Methyl-N-acetyl-D-glucosamine 3-O-Methyl-GlcNAc	Others	Metabolic Disease
3-O-Methyl-N-acetyl-D-glucosamine is a potent inhibitor of N-acetylglucosamine kinase. 3-O-Methyl-N-acetyl-D-glucosamine potently inhibits glucose phosphorylation by N-acetylglucosamine kinase whereas glucokinase is not at all affected by this hexosamine .

HY-101788

Glucokinase activator 1	Glucokinase	Metabolic Disease
Glucokinase activator 1 is a liver-directed *glucokinase* activator with an EC₅₀ of 34 nM.

HY-116946

Glucokinase activator 6	Glucokinase	Metabolic Disease
Glucokinase activator 6 (compound 9) is a potent *glucokinase* activator, with an EC₅₀ of 0.09 μM. Glucokinase activator 6 can be used for type 2 diabetes (T2D) research .

HY-P3257B

*ADP-Specific glucokinase, thermococcus litoralis* ADP-Dependent hexokinase, thermococcus litoralis	Glucokinase	Neurological Disease Metabolic Disease Cancer
ADP-Specific glucokinase, thermococcus litoralis is an ADP-specific glucose kinase expressed in thermophilic archaea. ADP-Specific glucokinase, thermococcus litoralis can catalyze glucose into glucose-6-phosphate, which promotes glycolysis. ADP-Specific glucokinase, thermococcus litoralis can activate T cells and enhance the phagocytic activity of macrophages. ADP-Specific glucokinase, thermococcus litoralis can be used in research on metabolic diseases, neurological disorders, and tumors .

HY-P3257A

*ADP-specific glucokinase, pyrococcus furiosus* ADP-dependent hexokinase, pyrococcus furiosus	Glucokinase	Neurological Disease Metabolic Disease Cancer
ADP-Specific glucokinase, pyrococcus furiosus is an ADP-specific glucose kinase expressed in thermophilic archaea. ADP-Specific glucokinase, pyrococcus furiosus can catalyze glucose into glucose-6-phosphate, which promotes glycolysis. ADP-Specific glucokinase, pyrococcus furiosus can activate T cells and enhance the phagocytic activity of macrophages. ADP-Specific glucokinase, pyrococcus furiosus can be used in research on metabolic diseases, neurological disorders, and tumors .

HY-121070

AZD1092	Glucokinase	Metabolic Disease
AZD1092 is an orally active glucokinase (GK) activator with an EC₅₀ value of 0.03 μM. AZD1092 can be used for the research of Type 2 Diabetes (T2D) .

HY-12411

AMG-3969 1 Publications Verification	Glucokinase	Metabolic Disease
AMG-3969 is a potent glucokinase-glucokinase regulatory protein interaction (GK-GKRP) disruptor with an IC₅₀ of 4 nM.

HY-100221

AM-2394	Glucokinase	Metabolic Disease
AM-2394 is a structurally distinct *glucokinase* activator (GKA). AM-2394 activates glucokinase (GK) with an EC₅₀ of 60 nM.

HY-19843

MK-0941	Glucokinase	Metabolic Disease
MK-0941 is a potent, orally active and allosteric *glucokinase* activator, with EC₅₀s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 has potential in the treatment of type 2 diabetes .

HY-U00411

PSN-GK1	Glucokinase	Metabolic Disease
PSN-GK1 is a potent *glucokinase* activator with an EC₅₀ of 0.13 μM.

HY-116682

GKA-71	Glucokinase	Metabolic Disease
GKA-71 is an orally active *Glucokinase* activator, possesses an islet protective effect .

HY-136631

PF-04279405	Glucokinase	Metabolic Disease
PF-04279405 is a potent and full-acting glucokinase (GK) agonist (EC₅₀=23 nM). Glucokinase (GK) is an enzyme responsible for the conversion of glucose to glucose-6-phosphate and plays a key role in maintaining blood glucose homeostasis. PF-04279405 can be used in the research of type 2 diabetes .

HY-19843A

MK-0941 free base	Glucokinase	Metabolic Disease
MK-0941 free base is an orally active *glucokinase* activator, with EC₅₀s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 free base exhibits strong glucose-lowering activity and is a potential therapeutic agent for treatment of type 2 diabetes .

HY-100181

PF-04991532	Glucokinase	Metabolic Disease
PF-04991532 is a potent, hepatoselective *glucokinase* activator with EC₅₀s of 80 and 100 nM in human and rat, respectively.

HY-133127A

AR453588 hydrochloride	Glucokinase	Metabolic Disease
AR453588 hydrochloride is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC₅₀ of 42 nM. AR453588 hydrochloride shows anti-hyperglycemic activity .

HY-133127

AR453588	Glucokinase	Metabolic Disease
AR453588 is a potent and orally bioavailable anti-diabetic *glucokinase* activator, with an EC₅₀ of 42 nM. AR453588 shows anti-hyperglycemic activity .

HY-100181B

(R)-PF-04991532	Others	Metabolic Disease
(R)-PF-04991532 is the R-enantiomer of PF-04991532 (HY-100181). PF-04991532 is a potent, hepatoselective glucokinase activator.

HY-109030

Dorzagliatin HMS5552	Glucokinase	Metabolic Disease
Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes .

HY-12614

AMG-1694	Glucokinase	Metabolic Disease
AMG-1694 is a potent glucokinase–glucokinase regulatory protein (GK-GKRP) disruptors and promotes the dissociation of the GK-GKRP complex with an IC₅₀ of 7 nM, indirectly increasing GK enzymatic activity. AMG-1694 potently reverses the inhibitory effect of GKRP on GK activity and promotes GK translocation. AMG-1694 normalizes blood glucose levels in several rodent models of diabetes and lowes blood glucose restricted to diabetic and not normoglycaemic animals .

HY-119813

(S,S)-Sinogliatin (S,S)-HMS-5552; (S,S)-RO-5305552	Glucokinase	Metabolic Disease
(S,S)-Sinogliatin ((S,S)-HMS-5552) is the (S,S) -enantiomer of Sinogliatin. Sinogliatin is a *glucokinase* activator that can be used to study type 2 diabetes .

HY-14747

Piragliatin RO4389620	Glucokinase	Metabolic Disease
Piragliatin (RO4389620) is an activator for *glucokinase*, which reduces endogenous glucose production, increases β-cell function and glucose utilization, and thus decreases the blood glucose levels. Piragliatin exhibits antidiabetic efficacy .

HY-109030R

Dorzagliatin (Standard) HMS5552 (Standard)	Glucokinase	Metabolic Disease
Dorzagliatin (Standard) is the analytical standard of Dorzagliatin. This product is intended for research and analytical applications. Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes .

HY-108328

Nerigliatin PF-04937319	Glucokinase	Metabolic Disease
Nerigliatin (PF-04937319) is a glucokinase activator (GKA) with EC₅₀ value of 154.4 μM, one of the most promising strategies for the treatment of type 2 diabetes mellitus . Nerigliatin is designed to maintain glucose-lowering efficacy while mitigating the risk of hypoglycaemia observed with many other GKAs .

HY-13529

Globalagliatin 1 Publications Verification LY2608204	Glucokinase	Metabolic Disease
Globalagliatin (LY2608204) is an orally active glucokinase (GK) activator with an EC₅₀ of 42 nM. Globalagliatin also stimulates glucose metabolism in rat insulinoma INS1-E cells with EC₅₀ of 579 nM. Globalagliatin targets both pancreatic β-cells and hepatocytes. Globalagliatin is promising for research of type 2 diabetes .

HY-144289

BMS-820132	Glucokinase	Metabolic Disease
BMS-820132 is an orally active and partial *glucokinase* (GK) activator with a AC₅₀ of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation .

HY-156020

Glucocerebrosidase-IN-2	Glucosidase	Metabolic Disease
Glucocerebrosidase-IN-2 (compound 12) is a quinazoline analogue and an inhibitor of glucocerebrosidase (GC). Glucocerebrosidase-IN-2 has the potential to improve GC translocation to lysosomes in Gaucher disease patient-derived cells (mostly carrying the N370S mutation). Glucocerebrosidase-IN-2 inhibits the hydrolysis of 4-methylumbelliferone β-D-glucopyranoside (4MU) and fluorescent glycosylceramide (FlourGC) in N370S mutant tissues with an AC50 of 25.29 μM .

HY-125316

AMG-151 ARRY-403	Others	Metabolic Disease
AMG-151 (ARRY-403) is a glucokinase agonist with fasting plasma glucose (FPG) lowering activity. AMG-151 showed a significant linear dose-response trend compared with placebo in a randomized, placebo-controlled Phase IIa study. The use of AMG-151 was associated with a higher incidence of hypoglycemia and hypertriglyceridemia. AMG-151 may serve as a potential compound for the inhibition of type 1 diabetes .

HY-15671

GKA50	Glucokinase	Metabolic Disease
GKA50 is a potent *glucokinase* activator (EC₅₀=33 nM at 5 mM glucose). GKA50 stimulates insulin release from mouse islets of Langerhans. GKA50 is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca ²⁺-dependent modulator of insulin secretion. GKA50 shows significant glucose lowering in high fat fed female rats .

HY-15671A

GKA50 quarterhydrate	Glucokinase	Metabolic Disease
GKA50 quarterhydrate is a potent *glucokinase* activator (EC₅₀=33 nM at 5 mM glucose) and stimulates insulin release from mouse islets of Langerhans. GKA50 quarterhydrate is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca ²⁺-dependent modulator of insulin secretion. GKA50 quarterhydrate shows significant glucose lowering in high fat fed female rats .

Cat. No.	Product Name

HY-L058

Glycolysis Compound Library	740 compounds
Glycolysis is a series of metabolic processes by which one molecule of glucose is catabolized to two molecules of pyruvate with a net gain of two ATP. Glycolysis takes place in 10 steps and catalyzed by a series of enzyme, such as hexokinase, Glucose-6-phosphate isomerase, Phosphofructokinase, etc. Glycolysis is used by all cells in the body for energy generation. Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications. MCE provides a unique collection of 740 glycolysis compounds that mainly target hexokinase, glucokinase, enolase, pyruvate kinase, PDHK, etc. MCE Glycolysis Compound Library is a useful tool for glucose metabolism research and anti-cancer drug discovery.

Glycolysis Compound Library

740 compounds

Glycolysis is a series of metabolic processes by which one molecule of glucose is catabolized to two molecules of pyruvate with a net gain of two ATP. Glycolysis takes place in 10 steps and catalyzed by a series of enzyme, such as hexokinase, Glucose-6-phosphate isomerase, Phosphofructokinase, etc. Glycolysis is used by all cells in the body for energy generation.

Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications.

MCE provides a unique collection of 740 glycolysis compounds that mainly target hexokinase, glucokinase, enolase, pyruvate kinase, PDHK, etc. MCE Glycolysis Compound Library is a useful tool for glucose metabolism research and anti-cancer drug discovery.

Species:	Human (2)
Tag:	His (1) Tag Free (2)
Source:	P. pastoris (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P75790

	Glucokinase/GCK Protein, Human Hexokinase-4; HK4; Hexokinase-D; Glucokinase	Human	E. coli
	Glucokinase/GCK proteins catalyze hexose phosphorylation, converting D-glucose, D-fructose, and D-mannose into their respective hexose 6-phosphates. Glucokinase/GCK Protein, Human is the recombinant human-derived Glucokinase/GCK protein, expressed by E. coli , with tag free.

HY-P71822

	GCKR Protein, Human (P.pastoris, His) FGQTL5; GCK ; GLRE; Glucokinase regulatory protein; Hexokinase 4 regulator; Hexokinase-D; HK IV; HK4	Human	P. pastoris
	The GCKR protein plays a critical regulatory role in glucokinase (GCK) by forming an inactive complex and recruiting GCK to the nucleus after meals. Its interaction with GCK is finely tuned by fructose metabolites; binding of GCKR to fructose-6-phosphate increases the affinity for GCK, whereas binding to fructose-1-phosphate decreases the affinity, thereby releasing inhibition. GCKR Protein, Human (P.pastoris, His) is the recombinant human-derived GCKR protein, expressed by P. pastoris , with N-His labeled tag.

HY-P703524

	*Polyphosphate glucokinase* Protein, Thermobifida fusca** Thermobifida fusca (strain YX); Kinase; Transferase	Others	E. coli

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82295

	Glucokinase Antibody (YA2040) GCK; Glucokinase; Hexokinase type IV; HK IV; Hexokinase-4; HK4; Hexokinase-D	WB	Human
	Glucokinase Antibody (YA2040) is a biotin-conjugated non-conjugated IgG antibody, targeting Glucokinase, with a predicted molecular weight of 52 kDa (observed band size: 52 kDa). Glucokinase Antibody (YA2040) can be used for WB experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: